• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 439516 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1414071131 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1414071131 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Valeant Pharmaceuticals International: 52-Week High Recently Eclipsed (VRX)

Published on Fri, 02/08/2013 - 15:25
By Mallory Stone

Valeant Pharmaceuticals International (NYSE:VRX) traded today at a new 52-week high of $67.98. This new high was reached on below average trading volume as 576,000 shares traded hands, while the average 30-day volume is approximately 1.4 million shares.

Valeant Pharmaceuticals International share prices have moved between a 52-week high of $67.98 and a 52-week low of $42.47 and are now trading 59% above that low price at $67.71 per share. The 200-day and 50-day moving averages have moved 0.43% higher and 1.50% higher over the past week, respectively.

Valeant Pharmaceuticals International has overhead space with shares priced $67.71, or 6.1% below the average consensus analyst price target of $72.13. The stock should find initial support at its 50-day moving average (MA) of $61.45 and further support at its 200-day MA of $54.13.

Valeant Pharmaceuticals International is a research-based, specialty pharmaceutical company that markets its products worldwide. The Company discovers, develops, manufactures, and markets a range of pharmaceutical products, focusing on products in the areas of infectious disease, neurology, and dermatology.

By Mallory Stone
mstone@fnno.com

Latest News from FNNO

Analysis of Relative Performance in the ...

Analysis was conducted on the Steel industry to measure relative performance to find st ...

Analysis of Relative Performance in the ...

Below are five companies in the Specialty Stores industry that underperformed yesterday ...

Senomyx has Relatively Underperformed it...

Analysis was conducted on the Specialty Chemicals industry to measure relative performa ...

Shares of Hospitality Properties Trust U...

Analysis was conducted on the Specialized REITs industry to measure relative performanc ...

Cree has Relatively Underperformed its P...

Below are five companies in the Semiconductors industry that underperformed yesterday o ...

Shares of Veeco Instruments Underperform...

Here are 5 stocks in the Semiconductor Equipment industry ranked by performance. We co ...

Shares of Buffalo Wild Wings Underperfor...

Below are five companies in the Restaurants industry that underperformed yesterday on a ...

Analysis of Relative Performance in the ...

Here are 5 stocks in the Regional Banks industry ranked by performance. We compiled th ...